Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Spina

Showing results (171-180 of 221) with videos related to

Pageof 23
Sort By:
Clinical and Experimental Immunology|March 6, 2007
Proteins specifically hyperexpressed in a coeliac disease patient with aberrant T cellsV De Re, M P Simula, L Caggiari, et al.
Journal of Chemotherapy (Florence, Italy)|June 28, 2007
Cetuximab/targeted chemotherapy in an HIV-positive patient with metastatic colorectal cancer in the HAART era: a case reportM Berretta, F Martellotta, C Simonelli, et al.
Journal of Medical Virology|March 26, 2009
Plasma HHV-8 viral load in HHV-8-related lymphoproliferative disorders associated with HIV infectionC Simonelli, R Tedeschi, A Gloghini, et al.
Clinical and Diagnostic Laboratory Immunology|September 6, 2000
Hepatitis E virus immunoglobulin G antibodies in different populations in Campinas, BrazilN S Gonçales, J R Pinho, R C Moreira, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 28, 2002
Intensified CHOP regimen in aggressive lymphomas: maximal dose intensity and dose density of doxorubicin and cyclophosphamideM Balzarotti, M Spina, B Sarina, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 16, 2001
Randomized phase III trial of high-dose-intensity methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) chemotherapy and recombinant human granulocyte colony-stimulating factor versus classic MVAC in advanced urothelial tract tumors: European Organization for Research and Treatment of Cancer Protocol no. 30924C N Sternberg, P H de Mulder, J H Schornagel, et al.
Journal of Neuroscience Research|June 22, 1999
Structural and compositional determinants of cortistatin activityJ R Criado, H Li, X Jiang, et al.
Cancer Radiotherapie : Journal De La Societe Francaise De Radiotherapie Oncologique|June 11, 2019
The German Hodgkin Study Group risk model is useful for Hodgkin lymphoma patients receiving radiotherapy after autologous stem cell transplantC Furlan, F Matrone, M Rupolo, et al.
British Journal of Cancer|January 22, 2004
Area under the curve of methotrexate and creatinine clearance are outcome-determining factors in primary CNS lymphomasA J M Ferreri, E Guerra, M Regazzi, et al.
European Journal of Cancer (Oxford, England : 1990)|December 7, 2005
Seven year update of an EORTC phase III trial of high-dose intensity M-VAC chemotherapy and G-CSF versus classic M-VAC in advanced urothelial tract tumoursC N Sternberg, P de Mulder, J H Schornagel, et al.
Pageof 23

Showing results (171-180 of 221) with videos related to

Sort By:
Pageof 23
Clinical and Experimental Immunology|March 6, 2007
Proteins specifically hyperexpressed in a coeliac disease patient with aberrant T cellsV De Re, M P Simula, L Caggiari, et al.
Journal of Chemotherapy (Florence, Italy)|June 28, 2007
Cetuximab/targeted chemotherapy in an HIV-positive patient with metastatic colorectal cancer in the HAART era: a case reportM Berretta, F Martellotta, C Simonelli, et al.
Journal of Medical Virology|March 26, 2009
Plasma HHV-8 viral load in HHV-8-related lymphoproliferative disorders associated with HIV infectionC Simonelli, R Tedeschi, A Gloghini, et al.
Clinical and Diagnostic Laboratory Immunology|September 6, 2000
Hepatitis E virus immunoglobulin G antibodies in different populations in Campinas, BrazilN S Gonçales, J R Pinho, R C Moreira, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 28, 2002
Intensified CHOP regimen in aggressive lymphomas: maximal dose intensity and dose density of doxorubicin and cyclophosphamideM Balzarotti, M Spina, B Sarina, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 16, 2001
Randomized phase III trial of high-dose-intensity methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) chemotherapy and recombinant human granulocyte colony-stimulating factor versus classic MVAC in advanced urothelial tract tumors: European Organization for Research and Treatment of Cancer Protocol no. 30924C N Sternberg, P H de Mulder, J H Schornagel, et al.
Journal of Neuroscience Research|June 22, 1999
Structural and compositional determinants of cortistatin activityJ R Criado, H Li, X Jiang, et al.
Cancer Radiotherapie : Journal De La Societe Francaise De Radiotherapie Oncologique|June 11, 2019
The German Hodgkin Study Group risk model is useful for Hodgkin lymphoma patients receiving radiotherapy after autologous stem cell transplantC Furlan, F Matrone, M Rupolo, et al.
British Journal of Cancer|January 22, 2004
Area under the curve of methotrexate and creatinine clearance are outcome-determining factors in primary CNS lymphomasA J M Ferreri, E Guerra, M Regazzi, et al.
European Journal of Cancer (Oxford, England : 1990)|December 7, 2005
Seven year update of an EORTC phase III trial of high-dose intensity M-VAC chemotherapy and G-CSF versus classic M-VAC in advanced urothelial tract tumoursC N Sternberg, P de Mulder, J H Schornagel, et al.
Pageof 23